REMARKS

Claims 32-56 are pending in the application. Claim 43 and the paragraph beginning at page 11, line 24, of the specification have been amended to correct a typographical error that listed the "VP1" rotavirus polypeptide as "BP1." The correct VP1 nomenclature appears in the specification in Table 1 (page 36) as well as in the Swiss Prot Accession P35942 that is referenced in Table 1. These amendments add no new matter.

Response to Restriction Requirement

In response to the requirement for restriction, applicants elect the invention of Group I, drawn to the embodiment of claims 32-51. In addition, applicants elect the following species: (1) a polymer comprising lactide and glycolide; and (2) a rotavirus VP1 polypeptide. Claims 32-51 read on the elected species. The elections are made without traverse.

CONCLUSION

Applicants request that the claims be examined. Attached hereto is a marked-up version of the changes made by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 12020-003002.

Respectfully submitted,

Date: November 1, 2002

Jack Brennan
Reg. No. 47,443

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Version with Markings to Show Changes Made

In the Specification:

The paragraph beginning at page 11, line 24, has been amended as follows:

(a) the antigens FHA, PT, 68 kd-Pertactin, tetanus toxin, gp48, NS1, Capsid, gp350, NS3, SA, I, NP_1, E, M, gp340, F, H, HN, 35 kd protein, VP1 [BP1], E1, E2, C, M, E and MSHA according to table 1; and

(b) immunogenic fragments, variants and derivatives of the polypeptides of (a).

In the Claims:

Claim 43 has been amended as follows:

43. (Amended) A pharmaceutical composition comprising a plurality of polymer microparticles and a pharmaceutically acceptable carrier, wherein the microparticles contain an aqueous solution of DNA, the aqueous solution of DNA has an alcohol content of 1 to 40%, and the DNA comprises a coding sequence encoding a polypeptide selected from the group consisting of:

(a) antigens FHA, PT, 68kd-Pertacin, tetanus toxin, gp-48, NS1, Capsid, gp350, NS3, SA, I, NP, E, M, gp340, F, H, HN, 35kd protein, VP1 [BP1], E1, E2, C, M, E and MSHA; and

(b) immunogenic fragments of the polypeptides of (a).